Replies to post #9105 on Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

from Dew -

Teva’s thrice-weekly Copaxone will be reviewed under an NDA. If approved, it could cannibalize some of the market for regular Copaxone, including the generic versions; however, thrice-weekly Copaxone will require an explicit prescription and won’t be substitutable for an Rx written for regular Copaxone.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=72989576

from Genisi -

The thrice-weekly Copaxone formulation (GALA study) is not low volume, rather it's a stronger dose (40mg glatiramer acetate instead of 20mg).

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=72990439&txt2find=gala

[DewDiligence]

Teva’s own PR on thrice-weekly Copaxone:

#msg-76611659

Note that the comparator in the GALA study was placebo, not the regular formulation of Copaxone.

Please see #msg-76610683 for related info.